GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Dr Reddys Laboratories Ltd
Dr Reddy's: USFDA inspection at Srikakulam plant yields 3 observations
REGULATORY ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 29 Jul 2026, 09:38 PM IST  ·  BSE ID: 0ccd144c-9d17-448d-8d1e-be4026ecb06e
View Original BSE Filing (PDF)
💡
In Simple Terms
Dr. Reddy's facility in Srikakulam was inspected by the US drug regulator, resulting in three observations that the company will resolve.
🤖 AI Summary
  • USFDA completed inspection of Dr. Reddy's Srikakulam facility between July 20-29, 2026.
  • The inspection included pre-approval and Good Manufacturing Practices (GMP) assessments.
  • A Form 483 was issued with three observations from the regulatory body.
  • Dr. Reddy's will address the observations within the stipulated timeline.
🏢 How This Affects the Company
⚙️
Operational Impact
The company must address the three observations noted in the Form 483 to ensure ongoing compliance and operational continuity for the Srikakulam facility.
⚠️
Risk Impact
The issuance of a Form 483 introduces a compliance risk that requires prompt attention to avoid potential delays or disruptions in product approvals or market access.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders. Monitor company communications regarding the resolution of the USFDA observations.
👤
Who Is Affected
All shareholders are affected as the timely resolution of USFDA observations impacts the company's regulatory compliance and operational status.
🔍
Management Signal
The company signals a commitment to regulatory compliance by promptly stating its intention to address the USFDA observations.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Company's detailed response to the 3 USFDA observations.
Updates on the timeline for addressing Form 483 observations.
Any further communications from USFDA regarding the Srikakulam plant.
MEDIUM RISK USFDA observations necessitate active management response and carry potential regulatory implications.
💡 Investor Takeaway
Dr. Reddy's Srikakulam facility received three observations from a USFDA inspection. The company will address these within the stipulated timeline, the details of which are pending.
❓ Frequently Asked Questions
When was the USFDA inspection conducted at Dr. Reddy's Srikakulam facility?
The USFDA conducted the inspection at Dr. Reddy's Srikakulam facility between July 20, 2026, and July 29, 2026.
What was the outcome of the USFDA inspection at Dr. Reddy's Srikakulam plant?
The USFDA issued a Form 483 with three observations following the inspection of Dr. Reddy's Srikakulam facility.
What type of inspection did the USFDA perform at Dr. Reddy's Srikakulam facility?
The USFDA performed a Pre-Approval Inspection (PAI) and a Good Manufacturing Practices (GMP) inspection at the facility.
Will Dr. Reddy's address the USFDA observations?
Yes, Dr. Reddy's Laboratories stated they will address the three observations issued by the USFDA within the stipulated timeline.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.